Ref ID: 19349
Author:
B. Sendid and O. Marchetti
Author address:
Lille University Hospital, University Lille 2, France and Centre
Hospitalier Universitaire Vaudois, Lausanne, Switserland
Full conference title:
6th Trends in Medical Mycology 2013
Date: 11 October 2014
Abstract:
Invasive fungal diseases (IFDs) are common life-threatening compli-
cations in immunocompromised and critically ill patients. Evolving
underlying conditions and antifungal strategies have modified the
epidemiology of IFDs. For yeast infections a shift toward non-albicans
Candida species and an increasing incidence of candidemia have been
observed in many countries, IFDs caused by molds, including asper-
gillosis and emerging fungi are increasingly reported, particularly in
the hemato-oncological and ICU settings.
In view of the severe morbidity and high mortality of IFDs, accu-
rate diagnostic techniques allowing timely onset of adequate antifun-
gal therapy are of outstanding importance. Although conventional
approaches such as microscopy, culture, histopathological examina-
tion, and imaging methods represent the diagnostic gold standard,
low sensitivity and/or specificity as well as delayed positivity are their
major limitations.
New non-invasive non-culture-based diagnostic techniques, includ-
ing assays form the detection of fungal antigens (e.g. galactomannan,
mannan, (1,3)-beta-d-glucan) in blood and biological fluids and of
circulating antibodies directed against fungal polysaccharides and
proteins (e.g. anti-mannan, anti-galactomannan) as well as molecu-
lar-based tools (e.g. panfungal and species-specific PCRs detecting
fungal DNA in blood and tissues) have been developed during the
last decade. Some of them are now included as standard microbiolog-
ical criteria in the international diagnostic classification of IFDs by
the EORTC-MSG expert panel and are routinely used by clinicians as
diagnostic adjuncts for the early documentation of a fungal etiology
in febrile patients at high risk of IFD and presenting with suggestive
clinical and radiological findings.
This meet-the-expert session will be devoted to interactive case pre-
sentations giving an overview on indications, strengths, and draw-
backs of these biomarkers for an early and accurate diagnosis of IFDs.
Abstract Number: m10
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a